tazobactam has been researched along with Skin Diseases, Bacterial in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
| Buonomo, AR; Congera, P; Foggia, M; Gentile, I; Maraolo, AE; Parente, S; Scotto, R; Zappulo, E | 1 |
| Bassetti, M; Castaldo, N; Givone, F; Peghin, M; Righi, E; Sartor, A | 1 |
| Arcenillas, P; Boix-Palop, L; Calbo, E; Cuchi, E; Dietl, B; Gómez, L; González de Molina, FJ; Nicolás, J; Sánchez, I | 1 |
| Artioli, S; Bassetti, M; Capone, A; Carannante, N; Castaldo, N; Cattelan, A; Cipriani, L; Coletto, D; Digaetano, M; Grossi, P; Losito, AR; Mastroianni, CM; Menichetti, F; Mussini, C; Nicolè, S; Peghin, M; Righi, E; Russo, A; Tascini, C; Tumbarello, M; Vena, A | 1 |
| Crespo Casal, M; Martinez-Lamas, L; Nodar, A; Perez-Landeiro, A; Perez-Rodríguez, MT; Sousa Dominguez, A | 1 |
| Citron, DM; Gesser, RM; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, Y | 1 |
| File, TM; Tan, JS | 1 |
| Duncanson, FP; Norden, CW; Talan, DA; Tan, JS; Wishnow, RM | 1 |
1 review(s) available for tazobactam and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Clavulanic Acid; Clavulanic Acids; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Necrosis; Penicillanic Acid; Piperacillin; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Ticarcillin | 1994 |
2 trial(s) available for tazobactam and Skin Diseases, Bacterial
| Article | Year |
|---|---|
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Double-Blind Method; Enzyme Inhibitors; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Bacterial; Tazobactam | 2002 |
Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.
Topics: Bacteroides Infections; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Tazobactam; Ticarcillin | 1993 |
6 other study(ies) available for tazobactam and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
Topics: Asia; Cephalosporins; Europe; Female; Global Health; Humans; Latin America; Male; Microbial Sensitivity Tests; North America; Pacific Islands; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Sepsis; Skin Diseases, Bacterial; Tazobactam | 2020 |
Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2020 |
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2017 |
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2019 |
Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam | 2017 |